Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2004-09-17
2011-12-06
Parkin, Jeffrey (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C536S023720
Reexamination Certificate
active
08071107
ABSTRACT:
The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
REFERENCES:
patent: 2003/0044421 (2003-03-01), Emini et al.
patent: 2003/0096778 (2003-05-01), Shiver et al.
patent: 2009/0162384 (2009-06-01), Haynes
patent: 2003-523188 (2003-08-01), None
patent: WO 01/60838 (2001-08-01), None
Leitner et al, eds., “HIV Sequence Compendium 2003”, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, LA-UR No. 04-7420, pp. 513-573 and attached appendix.
Supplementary Partial European Search Report dated Aug. 1, 2008—EP Appln. No. 04 78 4298.
Gaschen et al, “Diversity Considerations in HIV-1 Vaccine Selection”, Science 296 (5577):2354-2360 (2003).
Nickle et al, “Consensus and Ancestral State HIV Vaccines”, Science 299(5612):1515-1518 (2003).
Gao et al, “Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity”, Expert Rev. Vaccines 3(4):S161-168 (2004).
Wang, Lai-Xi, “Bioorganic Approaches Towards HIV Vaccine Design”, Current Pharmaceutical Design 9:1771-1787 (2003).
Gallo, Robert C., “The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years”, The Lancet 366:1894-1898 (2005).
Walker and Burton, “Toward an AIDS Vaccine”, Science 320:760-764 (2008).
Levine, Arnold J., “Why Do We Not Yet Have a Human Immunodeficiency Virus Vaccine?”, Journal of Virology 82(24):11998-1200 (2008).
Gao et al, “Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity”, Expert Rev Vaccines 3(4 Suppl)S161-8 (2004)—Abstract.
Liao et al, “A Group M Consensus Envelope Glycoprotein induces Antibodies That Neutralize Subsets of Subtype B and C HIV-1 Primary Viruses”, NIH Public Access, pp. 1-30, Published in final edited form as Virology 353(2):268-282 (2006).
Williamson et al, “Characterization and selection of HIV-1 subtype C isolates for use in vaccine development”, AIDS Res. Hum. Retroviruses 19(2):133-144 (2003) —Abstract.
Novitsky et al, “Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequences for an AIDS Vaccine Design?”, Journal of Virology 66(11):5435-5451 (2002).
Ellenberger et al, “Generation of a Consensus Sequence from Prevalent and Incident HIV-1 Infections in West Africa to Guide AIDS Vaccine Development”, Virology 302:156-163 (2002).
Deml et al, “Multiple Effects of Codon Usage Optimization on Expression and Immunogenicity of DNA Candidate Vaccines Encoding the Human Immunodeficiency Virust Type 1 Gag Protein”, Journal of Virology 75(22):10991-11001 (2001).
Gao et al, “Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice”, AIDS Res. Hum. Retroviruses 19(9):817-823 (2003) —Abstract.
Kofman et al, “HIV-1 gag expression is quantitatively dependent on the ratio of native and optimized codons”, Tsitologiia 45(1):86-93 (2003)—Abstract.
Decker Julie
Gao Feng
Hahn Beatrice H.
Haynes Barton F.
Korber Bette T.
Duke University
Nixon & Vanderhye P.C.
Parkin Jeffrey
The Regents of the University of California
The University of Alabama at Birmingham Research Foundation
LandOfFree
Nucleic acids encoding modified human immunodeficiency virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding modified human immunodeficiency virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding modified human immunodeficiency virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4301595